ISRCTN32435732
Completed
未知
Qualification of predictive biomarkers for epidermal growth factor receptor tyrosine kinase inhibitor therapy in oesophagogastric adenocarcinoma
niversity of Aberdeen (UK)0 sites300 target enrollmentMarch 5, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- niversity of Aberdeen (UK)
- Enrollment
- 300
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients with oesophagogastric cancer must be eligible for and enrolled in the COG trial
- •2\. Ability to provide written informed consent
- •3\. Formalin\-fixed and paraffin\-embedded (FFPE) tumour material available
- •4\. Male and female participants
- •5\. Lower Age Limit 18 years
Exclusion Criteria
- •1\. Patients not enrolled in COG trial
- •2\. Inability to provide written informed consent
- •3\. No FFPE tumour material available for analysis
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
AMBITIOUSAtopic Dermatitis Biomarker Identification Trial in Omalizumab UsageSingle- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitis - AMBITIOUSAMBITIOUS is a trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitisAtopische Dermatitis is a common inflammatory skin disease showing chronically relapsing eczema and high association with elevated serum IgE levels.MedDRA version: 14.0Level: LLTClassification code 10029264Term: Neurodermatitis aggravatedSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2010-018559-84-DEMedizinische Fakultät der technischen Universität Muenchen20
Active, not recruiting
Phase 1
Skin bioMARkers for atopic eczema Therapy evaluatioatopic eczema (synonym atopic dermatitis) and the adverse treatment side effect epidermal atrophyMedDRA version: 21.1Level: LLTClassification code 10003641Term: Atopic eczemaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: PTClassification code 10040799Term: Skin atrophySystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2019-002643-23-GBSheffield Teaching Hospitals NHS Foundation Trust37
Active, not recruiting
Phase 2
Skin biomarkers for atopic eczema therapy evaluation study 2ISRCTN52806782Sheffield Teaching Hospitals NHS Foundation Trust40
Completed
Not Applicable
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other ParkinsonismParkinson DiseaseParkinsonismDementia With Lewy BodiesMultiple System AtrophyProgressive Supranuclear PalsyCorticobasal DegenerationNCT04518059University Hospitals Cleveland Medical Center184
Completed
Not Applicable
Elucidation of biomarkers to predict the presence of coronary vulnerable plaqueJPRN-UMIN000009806agasaki University Graduate School of Biomedical Sciences200